People

Stephen Oesterle

vensanacap.comlinkedin.comnovoholdings.com

Stephen Oesterle is a senior adviser to Patient Square Capital. He previously led medicine and technology at Medtronic and directed interventional cardiology programs at Stanford and Massachusetts General Hospital. He has also advised venture and private-equity investors in healthcare. Stephen Oesterle is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Baxter, Paragon 28, Medicine & Technology, Medtronic. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments. Between 2002 and 2015, Stephen was a member of Medtronic’s Executive Committee, serving as Senior Vice President for Medicine and Technology. In this role, he contributed to the company’s business development, operating plans and long-term strategies. In addition, Stephen had corporate oversight of Medtronic’s technology R&D, developing and leading collaborative relationships with technical universities, high tech corporations and medical device start-ups. Prior to this, Stephen served as Associate Professor of Medicine at the Harvard University Medical School and as Director of Invasive Cardiology Services at Massachusetts General Hospital, Boston. As a teacher and innovator in the field of cardiac catheterization, he also developed and directed interventional cardiology programmes at Good Samaritan Hospital, Los Angeles, as well as at the universities of Georgetown and Stanford. Stephen is independent director on several public and private boards in the USA, Switzerland, Germany and China. Stephen serves on a wide range of boards, including Baxter International (NYSE), Peijia Medical (Shanghai) Paragon 28 (NYSE), Private equity backed SHL Medical AG (Zürich) and  CeramTec (Germany) and venture backed Alcyone Therapeutics and Anuncia.